Citations Appearing in 2008

  1. Ambrose, Paul G., J.B. Anon, S.M. Bhavnani, Ó. Okusanya, R.N. Jones, M.R. Paglia, J. Kahn, G.L. Drusano. Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis. Diagnostic Microbiology and Infectious Disease 61(1):0732-8893, 2008.
  2. Baek, I., M. Yun, H. Yun and K. Kwon. Pharmacokinetic/pharmacodynamic modeling of the cardiovascular effects of beta blockers in humans. Archives of Pharmaceutical Research 31(6):814-821, 2008.
  3. Beumer, J.H., J.L. Eiseman, R.A. Parise, J.A. Florian Jr., E. Joseph, D.Z. D’Argenio, R.S. Parker, B. Kay, J.M. Covey and M.J. Egorin. Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice. Cancer Chemotherapy and Pharmacology 62(3):457-464, 2008.
  4. Brice, K., B. Valerie, G. Claire, M. Valerie, B. Yves, A. Gilles and B. Nathalie. Risk-Adjusted Monitoring of Veno-Occlusive Disease Following Bayesian Individualization of Busulfan Dosage for Bone Marrow Transplantation in Paediatrics. Pharmacoepidemiology and Drug Safety 17(2):135-43, 2008.
  5. Chadwick, E.G., E.V. Capparelli, R. Yogev, J.A. Pinto, B. Robbins, J.H. Rodman, J. Chen, P. Palumbo, L. Serchuck, E. Smith and M. Hughes, Michael. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. AIDS 22(2):249-255, 2008.
  6. Chiorean, E.G., J.M. Porter, A.E. Foster, A.S. Al Omari, C.A. Yoder, K.L. Fife, R.M. Strother, D.J. Murry, M. Yu, D.R. Jones and C.J. Sweeney. A phase I and pharmacokinetic trial of erlotinib in combication with weekly docetaxel in patient with taxane-naive malignancies. Clinical Cancer Research 14(4):1131-1137, 2008.
  7. Colucci, P., J. C. Pottage, H. Robison, J. Turgeon and M. P. Ducharme. The effect of a single-dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, when administered in healthy volunteers. Antimicrobial Agents and Chemotherapy 52:626-50, 2008.
  8. Di Verniero, C. A., E. A. Silberman, M. A. Mayer, J. A. W. Opezzo, C. A. Taira and C. Hocht. In Vitro and in Vivo Pharmacodynamic Properties of Metoprolol in Fructose-Fed Hypertensive Rats. Journal of Cardiovascular Pharmacology 51(6):532-41, 2008.
  9. Dong, J.Q., B. Chen, M.A. Gibbs, M. Emery, and J.P. Gibbs. Applications of computer-aided pharmacokinetic and pharmacodynamic methods from drug discovery through registration. Current Computer-Aided Drug Design 4(1):54-66, 2008.
  10. Drusano, G.L., O.O. Okusanya, A. Okusanya, B.V. Scoy, D.L. Brown, R. Kulawy, F. Sorgel, H.S. Heine and A. Louie. Is 60 days of Ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis? Antimicrobial Agents and Chemotherapy 52(11):3973-3979, 2008.
  11. Earp, Justin C., D.C. DuBois, D.S. Molano, N.A. Pyszczynski, C.E. Keller, R.R. Almon, and W. Jusko. Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in lewis rats. Journal of Pharmacology and Experimental Therapeutics 326(2):523-545, 2008.
  12. Earp, Justin C., D.C. DuBois, D.S. Molano, N.A. Pyszczynski, C.E. Keller, R.R. Almon, and W. Jusko. Modeling corticosteroid effects in a rat model of rheumatoid arthritis II: mechanistic pharmacodynamic model for dexamethasone effects in lewis rats with collagen-induced arthritis. Journal of Pharmacology and Experimental Therapeutics 326(2):546-554, 2008.
  13. Fiaccadori, E., U. Maggiore, E. Parenti, P. Greco and A. Cabassi. Sustained low-efficiency dialysis (SLED) for acute lithium intoxication. NDT Plus, 2008.
  14. Florian, J. A., J. L. Eiseman and R. S. Parker. Nonlinear Model Predictive Control for Dosing Daily Anticancer Agents Using a Novel Saturating-Rate Cell-Cycle Model. Computers in Biology and Medicine 38(3):339-47,2008.
  15. Granizoa, J.J., B. Sadaba, J. Honorato, M.J. Gimenez, D. Sevillano, L. Aguilar and P. Coronel. Monte Carlo simulation describing the pharmacodynamic profile of cefditoren in plasma from healthy volunteers. International Journal of Antimicrobial Agents 31(4):396-398, 2008.
  16. Gururangan, S., C. D. Turner, C. F. Stewart, M. O’Shaughnessy, M. Kocak, T. Y. Poussaint, P. C. Phillips, S. Goldman, R. Packer, I. F. Pollack, S. M. Blaney, V. Karsten, S. L. Gerson, J. M. Boyett, H.S. Friedman and L.E. Kun. Phase I Trial of VNP40101M (Cloretazine) in Children with Recurrent Brain Tumors: A Pediatric Brain Tumor Consortium Study. Clinical Cancer Research 14:1124, 2008.
  17. Hazra, A., N.A. Pyszczynski, D.C. DuBois, R.R. Almon and W.J. Jusko. Modeling of corticosteroid effects on hepatic low-density lipoprotein receptors and plasma lipid dynamics in rats.  Pharmaceutical Research 25(4):769-780, 2008.
  18. Hong, Y., F.M. Gengo, M.M. Rainka, V.E. Bates, D.E. Mager. Population Pharmacodynamic Modelling of Aspirin- and Ibuprofen-Induced Inhibition of Platelet Aggregation in Healthy Subjects. Clinical Pharmacokinetics 47(2):129-137, 2008.
  19. Hong, Y., J. Dingemanse, D.E. Mager. Pharmacokinetic/pharmacodynamic modeling of renin biomarkers in subjects treated with the renin inhibitor aliskiren. American Society of Clinical Pharmacology and Therapeutics 84(1):136-143, 2008.
  20. Hope, W.W., D. Mickiene, V. Petraitis, R. Petraitiene, A.M. Kelaher, J.E. Hughes, M.P. Cotton, J. Bacher, J.J. Keirns, D. Buell, G. Heresi, D.K. Benjamin Jr, A.H. Groll, G.L. Drusano and T.J. Walsh.The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. Journal of Infectious Diseases 197(1):163-171, 2008.
  21. Jacob, E., K. Scorsone, S.M. Blaney, D.Z. D’Argenio and S.L. Berg. Synergy of Karenitecin and Mafosfamide in Pediatric Leukemia, Medulloblastoma, and Neuroblastoma Cell Lines. Pediatric Blood Cancer 50:757-760, 2008.
  22. Jimeno, A., M. A. Rudek, T. Purcell, D. A. Laheru, W. A. Messersmith, J. Dancey, M. A. Carducci, S. D. Baker, M. Hidalgo and R. C. Donehower. Phase I and Pharmacokinetic Study of Ucn-01 in Combination with Irinotecan in Patients with Solid Tumors. Cancer Chemotherapy and Pharmacology 61:423-33, 2008.
  23. Kirstein, M.N., R.C. Brundage, M.M. Moore, B.W. Williams, L.A. Hillman, J.W. Dagit, J.E. FIsher, P.H.Marker, R.A. Kratzke and D. Yee. Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system. Cancer Chemotherapy and Pharmacology 61(2):291-299, 2008.
  24. Kirstein, M.N., S. Root, M.M. Moore, K.M. Wieman, B.W. Williams, P.A. Jacobson, P.A., Marker, P.H. and Tuttle, T.M. Exposure-response relationships for oxaliplatin-treated colon cancer cells. Anti-Cancer Drugs 19(1):37-44, 2008.
  25. Klitgaard, T., T.G. Nielsen. Overview of the human pharmacokinetics of recombinant activated factor VII. British Journal of Clinical Pharmacology 65(1):3-11, 2008.
  26. Krzyzanski, W. and E. Wyska. Pharmacokinetics and Pharmacodynamics of Erythropoietin Receptor in Healthy Volunteers. Naunyn-Schmiedeberg’s Archives of Pharmacology 377:637-45, 2008.
  27. Krzyzanski, W., J. J. Perez-Ruixo and A. Vermeulen. Basic Pharmacodynamic Models for Agents That Alter the Lifespan Distribution of Natural Cells. Journal of Pharmacokinetics and Pharmacodynamics 35(3):349-77, 2008.
  28. Lim, T.P., K.R. Ledesma, K.T. Chang, J.G. Hou, A.L. Kwa, M. Nikolaou, J.P. Quinn, R.A. Prince and V.H. Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy 52(8): 2898-2904, 2008.
  29. Lin, S., P. M. Beringer, L. Hidayat, A. P. Rao, S. Louie, G. J. Burckart and B. Shapiro. Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine. Journal of Clinical Pharmacology 48(8):957-65, 2008.
  30. Lodise, Jr. T.P., M. Gotfried, S. Barriere and G.L. Drusano. Telavancin penetration into human epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation. Antimicrobial Agents and Chemotherapy 52(7): 2300-2304, 2008.
  31. Lodise, T. P., M. Kinzig-Schippers, G. L. Drusano, U. Loos, F. Vogel, J. Bulitta, M. Hinder and F. Soergel. Use of Population Pharmacokinetic Modeling and Monte Carlo Simulation to Describe the Pharmacodynamic Profile of Cefditoren in Plasma and Epithelial Lining Fluid. Antimicrobial Agents and Chemotherapy 52(6):1945-51, 2008.
  32. Lonnerholm, G., B. M. Frost, J. Abrahamsson, M. Behrendtz, A. Castor, E. Forestier, M. Heyman, D. R. A. Uges and S. S. N. de Graaf. Vincristine Pharmacokinetics Is Related to Clinical Outcome in Children with Standard Risk Acute Lymphoblastic Leukemia. British Journal of Haematology 142(4):616-21, 2008.
  33. Lönnerholm, G., B. Frost, S. Söderhäll and S.S.N. de Graaf. Vincristine pharmacokinetics in children with down syndrome. Pediatric Blood and Cancer 52(1): 123-125, 2008.
  34. Louie, A., H.S. Heine, K. Kim, D.L. Brown, B. VanScoy, W. Liu, M. Kinzig-Schippers, F. Sorgel and G.L. Drusano. Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracisAntimicrobial Agents and Chemotherapy 52(7):2486-2496, 2008.
  35. MacDonald, T.J., C.F. Stewart, K. Mehmet, S. Goldman, R.G. Ellenbogen, P.Phillips, D. Lafond, T.Y. Poussaint, M.W. Kieran, J.M. Boyett and L.E. Kun. Phase I clinical trial of Cilengitide in children with refractory brain tumors: Pediatric brain tumor consortium study. Journal of Clinical Oncology 26(6):919-924, 2008.
  36. Marathe, A., M.C. Peterson and D.E. Mager. Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. The Journal of Pharmacology and Experimental Therapeutics 326(2): 555-562, 2008.
  37. Marraffa, J., A. Forrest, W. Grant, C. Stork, K. McMartin and M.A. Howland. Oral administration of fomepizole produces similar blood levels as identical intravenous dose. Clinical Toxicology (Philadelphia, Pa.) 46(3):181-186, 2008.
  38. Morin, V., J. R. E. del Castillo, S. Authier, N. Ybarra, C. Otis, D. Gauvin, J. Gutkowska and E. Troncy. Evidence for Non-Linear Pharmacokinetics of Oxytocin in Anesthetized Rat. Journal of Pharmacy and Pharmaceutical Sciences 11(4):12-24, 2008.
  39. Panetta, J.C., P. Schaiquevich, V.M. Santana and C.F. Stewart. Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma. Clinical Cancer Research 14(1):318-325, 2008.
  40. Pottier, N., W. J. Yang, M. Assem, J. C. Panetta, D. Q. Pei, S. W. Paugh, C. Cheng, M. L. Den Boer, M. V. Relling, R. Pieters, W. E. Evans and M. H. Cheok. The Swi/Snf Chromatin-Remodeling Complex and Glucocorticoid Resistance in Acute Lymphoblastic Leukemia. Journal of the National Cancer Institute 100(24):1792-803, 2008.
  41. Pronzato, L. Optimal Experimental Design and Some Related Control Problems. Automatica 44(2):303-25, 2008.
  42. Rosner, G.L., J.C. Panetta, F. Innocenti and M.J. Ratain. Pharmacogenetic pathway analysis of Irinotecan. Clinical Pharmacolody and Therapeutics 84(3):393-402, 2008.
  43. Ruangweerayut, R., S. Looareesuwan, D. Hutchinson, A. Chauemung, V. Banmairuroi and K. Na-Bangchang. Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malaria. Malaria Journal 7:225, 2008.
  44. Saleem, A., E. O. Aboagye, J. C. Matthews and P. M. Price. Plasma Pharmacokinetic Evaluation of Cytotoxic Agents Radiolabelled with Positron Emitting Radioisotopes. Cancer Chemotherapy and Pharmacology 61(5):865-73, 2008.
  45. Sermsappasuk, P., O. Abdelrahman and M. Weiss. Cardiac Pharmacokinetics and Inotropic Response of Verapamil in Rats with Endotoxemia. Journal of Pharmaceutical Sciences 97(7):2798-804, 2008.
  46. Shen, J., C. Fraga, C. Calabrese, M.B. McCarville, P. Schaiquevich and C.F. Stewart. A modified surgical procedure for microdialysis probe implantation in the lateral ventricle of a FVB mouse. Journal of Pharmaceutical Sciences 97(11): 5013-5023, 2008.
  47. Stapleton, S.L., P.A. Thompson, C. Ou, S.L. Berg, L. McGuffrey, B. Gibson and S.M. Blaney.  Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates. Cancer Chemotherapy and Pharmacology 61(4):647-652, 2008.
  48. Sowinski, K.M., S.J. Magner, M.K. Scott, R.J. Hamburger and B.A. Mueller. Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing. Clinical Journal of the American Society of Nephrology 3(2):355-361, 2008.
  49. Tam V.H., K.R. Ledesma, G. Vo, S. Kabbara, T.P. Lim and M. Nikolaou. Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. Antimicrobial Agents and Chemotherapy 52(11):3987-3993, 2008.
  50. Tisdale, J.E., B.R. Overholser, K.M. Sowinski, H.A. Worblewski, K. Amankwa, S. Borzak, J.R. Kingery, R. Coram, D.P. Zipes, D.A. Flockhart and R.J. Kovacs. Pharmacokinetics of Ibutilide in patients with heart failure due to left ventricular systolic dysfunction. Pharmacotherapy 28(12):1461-1470, 2008.
  51. Tod, M., F. Lagneau, V. Jullien and O. Mimoz. A physiological model to evaluate drug kinetics in patients with hemorrhagic shock followed by fluid resuscitation. Application to amoxicillin-clavulanate. Pharmaceutical Research 25(6):1431-1439, 2008.
  52. Thuy, L.T., L.N. Hung, P.T. Danh and K. Na-Bangchang. Absence of time-dependent artesunate pharmacokinetics in healthy subjects during 5-day oral administration. European Journal of Clinical Pharmacology 64(10):993-998.
  53. Vicini, P., A. B. Brill, M. G. Stabin and A. Rescigno. Kinetic Modeling in Support of Radionuclide Dose Assessment. Seminars in Nuclear Medicine 38(5):335-46, 2008.
  54. Wang, X. and M.E. Morris. Pharmacokinetics and bioavailability of the flavonoid 7,8-benzoflavone in rats. Journal of Pharmaceutical Sciences 97(10):4546–4556, 2008.
  55. Wang, J., M. Weiss and D.Z. D’Argenio. A note on population analysis of dissolution-absorption models using the inverse gaussian function. The Journal of Clinical Pharmacology 48:719-25.
  56. Wang, W., Q. Wang and M.E. Morris. Pharmacokinetic interaction between the flavonoid luteolin and γ-hydroxybutyrate in rats: potential involvement of monocarboxylate transporters. The AAPS Journal 10(1):47-55, 2008.
  57. Weiss, M. How Does Obesity Affect Residence Time Dispersion and the Shape of Drug Disposition Curves? Thiopental as an Example. Journal of Pharmacokinetics and Pharmacodynamics 35(3):325-36, 2008.
  58. Weiss, M., D.Y. Hung, K. Poenicke and M.S. Roberts. Kinetic analysis of saturable hepatic uptake of digoxin and its inhibition by rifampicin. European Journal of Pharmaceutical Sciences 34(4-5):345-350, 2008.
  59. Wilms, E. B., D. J. Touw and H. G. M. Heijerman. Pharmacokinetics and Sputum Penetration of Azithromycin During Once Weekly Dosing in Cystic Fibrosis Patients. Journal of Cystic Fibrosis 7(1):79-84, 2008.
  60. Woo, S., W. Krzyzanski and W. J. Jusko. Pharmacodynamic Model for Chemotherapy-Induced Anemia in Rats. Cancer Chemotherapy and Pharmacology 62(1):123-33, 2008.
  61. Yang, L., J.C. Panetta, X. Cai, W. Yang, D. Pei, C. Cheng, N. Kornegay, C.H. Pui and M.V. Relling. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. Journal of Clinical Oncology 26(12):1932-1939, 2008.
  62. Yao, Z. L., D. C. Dubois, R. R. Almon and W. J. Jusko. Pharmacokinetic/Pharmacodynamic Modeling of Corticosterone Suppression and Lymphocytopenia by Methylprednisolone in Rats. Journal of Pharmaceutical Sciences 97(7):2820-32, 2008.
  63. Yao, Z., E.P. Hoffman, S. Ghimbovschi, D.C. DuBois, R.R. Almon and W.J. Jusko. Mathematical modeling of corticosteroid pharmacogenomics in pat muscle following acute and chronic methylprednisolone dosing. Molecular Pharamceutics 5(2):328–339, 2008.
  64. Yao, Z., E.P. Hoffman, S. Ghimbovschi, D.C. DuBois, R.R. Almon and W.J. Jusko. Pharmacodynamic/pharmacogenomic modeling of insulin resistance genes in rat muscle after methylprednisolone treatment: exploring regulatory signaling cascades. Gene Regulation and Systems Biology 2:141–161, 2008.
  65. Yong, W. Wang, L., Tham, L., Wong, C., Lee, S., Soo, R., Sukri, N., Lee, H. and Goh, B. A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers. Cancer Chemotherapy and Pharmacology 62(2):243-251, 2008.
  66. Yue, C.S., W. Huang, M. Alton, A.N. Maroli, R.W. Waltrip, D. Wright and M.D. Marco. Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout. Journal of Clinical Pharmacology 48(6):708-718, 2008.
  67. Zahr, N., Z. Amoura, J. Debord, J. S. Hulot, F. Saint-Marcoux, P. Marquet, J. C. Piette and P. Lechat. Pharmacokinetic Study of Mycophenolate Mofetil in Patients with Systemic Lupus Erythematosus and Design of Bayesian Estimator Using Limited Sampling Strategies. Clinical Pharmacokinetics 47(4):277-84, 2008.
  68. Zamboni, W.C., L.L. Jung, S. Strychor, E. Joseph, B.A. Zamboni, S.A. Fetterman, B.K. Sidone, T.G. Burke, D.P. Curran and J.L. Eiseman. Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice. Investigational New Drugs 26(5):399-406, 2008.
  69. Zamboni, W.C., S. Strychor, E. Joseph, R.A. Parise, M.J. Egorin and J.L. Eiseman. Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts. Cancer Chemotherapy and Pharmacology 62(3):417-426, 2008.
  70. Zandvliet, A. S., J. H. M. Schellens, J. H. Beijnen and A. D. R. Huitema. Population Pharmacokinetics and Pharmacodynamics for Treatment Optimization in Clinical Oncology. Clinical Pharmacokinetics 47(8):487-513, 2008.